Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Regenxbio Inc (RGNX) USD0.0001

Sell:$38.51 Buy:$38.53 Change: $1.36 (3.41%)
NASDAQ:0.13%
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Sell:$38.51
Buy:$38.53
Change: $1.36 (3.41%)
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Sell:$38.51
Buy:$38.53
Change: $1.36 (3.41%)
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Contact details

Address:
9600 Blackwell Rd Ste 210
ROCKVILLE
20850-3655
United States
Telephone:
+1 (240) 5528181
Website:
regenxbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RGNX
ISIN:
US75901B1070
Market cap:
$1.47 billion
Shares in issue:
36.87 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Donald Hayden
    Independent Chairman of the Board
  • Kenneth Mills
    President, Chief Executive Officer, Executive Director
  • Vittal Vasista
    Chief Financial Officer
  • Curran Simpson
    Senior Vice President - Product Development, Chief Technology Officer
  • Patrick Christmas
    Senior Vice President, General Counsel
  • Steve Pakola
    Senior Vice President and Chief Medical Officer
  • Ram Palanki
    Senior Vice President - Commercial Strategy and Operations
  • Olivier Danos
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.